STOCK TITAN

Burning Rock Biotech Ltd - BNR STOCK NEWS

Welcome to our dedicated page for Burning Rock Biotech news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech stock.

Burning Rock Biotech Ltd (BNR) delivers precision oncology solutions through advanced genomic testing and cancer diagnostics. This news hub provides investors and healthcare professionals with essential updates on the company’s innovations in next-generation sequencing (NGS) technology and clinical developments.

Access authoritative reporting on BNR’s regulatory milestones, clinical study results, and strategic partnerships. The curated collection includes earnings announcements, product launch details, and progress in early cancer screening technologies. Each update is verified for clinical relevance and financial significance.

Key focus areas include therapy selection advancements for late-stage cancer patients, expansion of in-hospital testing capabilities, and developments in liquid biopsy technologies. Stay informed about BNR’s contributions to personalized cancer treatment protocols and diagnostic standardization efforts.

Bookmark this page for streamlined access to Burning Rock’s official communications. Regularly updated with validated information to support informed decision-making in oncology investments and clinical practice.

Rhea-AI Summary

Burning Rock Biotech (NASDAQ: BNR) has reported its Q4 and full-year 2024 financial results, showing mixed performance across different business segments. Q4 revenues increased 4.1% to RMB126.0 million (US$17.3 million), with a notable 50.9% growth in in-hospital business to RMB43.5 million, while central laboratory revenue declined 23.4% to RMB39.3 million.

The company's gross margin improved to 71.0% in Q4 2024 from 64.5% in Q4 2023. Operating expenses decreased by 29.9% to RMB171.3 million, driven by organizational optimization and cost-control measures. Net loss for Q4 2024 narrowed to RMB81.3 million (US$11.1 million) from RMB162.2 million in the prior year.

For full-year 2024, total revenue decreased 4.0% to RMB515.8 million, with in-hospital business growing 19.0% while central laboratory revenue declined 24.6%. The company's net loss for 2024 improved to RMB346.6 million from RMB653.7 million in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.36%
Tags
-
Rhea-AI Summary

Burning Rock Biotech (NASDAQ: BNR), a company specializing in NGS technology for precision oncology, announced that all resolutions proposed at its 2024 annual general meeting were approved by shareholders. The key resolutions included: the ratification of Ernst & Young Hua Ming LLP as the company's auditor for fiscal year 2024, the re-election of directors Yusheng Han and Gang Lu, and the authorization for directors to implement these resolutions at their discretion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
none
-
Rhea-AI Summary

Burning Rock Biotech (NASDAQ: BNR) reported Q3 2024 financial results with total revenues of RMB128.6 million (US$18.3 million), a 0.8% increase year-over-year. The company saw a 17% growth in in-hospital business revenue to RMB63.8 million, while central laboratory revenue decreased 25.2% to RMB40.0 million. Pharma R&D services revenue increased 27.1% to RMB24.9 million.

The company's gross profit increased 6.9% to RMB91.8 million, with gross margin improving to 71.4% from 67.4%. Operating expenses decreased 50.7% to RMB130.4 million due to reduced share-based compensation and improved efficiency. Net loss narrowed to RMB35.7 million from RMB175.0 million in the previous year. Cash and equivalents stood at RMB498.2 million as of September 30, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.67%
Tags
Rhea-AI Summary

Burning Rock Biotech (NASDAQ: BNR) has announced its Annual General Meeting (AGM) scheduled for December 31, 2024, at 10:00 a.m. local time at the company's Shanghai office. The AGM will address three key proposals: ratification of Ernst & Young Hua Ming LLP as auditor for FY2024, re-election of Yusheng Han and Gang Lu as directors, and authorization for directors to implement these resolutions. The record date is set for December 4, 2024, for shareholders and ADS holders to determine voting eligibility. The board fully supports these proposals and recommends shareholders vote in favor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
Rhea-AI Summary

Burning Rock Biotech (NASDAQ: BNR) and Dizal have jointly announced the approval of the first co-developed NGS-based companion diagnostic (CDx) for lung cancer by China's National Medical Products Administration (NMPA). This CDx is designed for EGFR exon 20 insertion mutation (exon20ins) for sunvozertinib, marking a significant milestone in precision oncology.

The approval is the result of simultaneous development of Burning Rock's LungCure CDx and Dizal's sunvozertinib therapy, offering an innovative precision treatment solution for non-small cell lung cancer patients with EGFR exon20ins. This collaboration sets a new benchmark for concurrent development of companion diagnostics for anti-tumor drugs and positions Burning Rock to drive global CDx development for pharmaceutical companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
-
Rhea-AI Summary

Burning Rock Biotech (NASDAQ: BNR) announced significant changes in its management and Board of Directors on September 27, 2024. Mr. Leo Li has resigned from his positions as a director on the company's Board and as the Chief Financial Officer, effective immediately. Mr. Li confirmed that his resignation was due to personal reasons and not related to any disagreements with the company.

In light of this change, Ms. Xiaozhi Hu, senior director in finance, will take charge of financial operations, reporting, and related matters. Ms. Hu, who joined Burning Rock in May 2014, will report directly to Mr. Yusheng Han, the chairman of the board and CEO. Mr. Han expressed gratitude for Mr. Li's contributions, particularly during the company's IPO and subsequent business development projects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
management
Rhea-AI Summary

Burning Rock Biotech (NASDAQ: BNR, LSE: BNR) reported its Q2 2024 financial results. Total revenues decreased by 7.3% to RMB135.5 million (US$18.7 million) compared to the same period in 2023. The in-hospital segment showed 11.2% growth, while the central laboratory business experienced a 26.4% decline. Gross profit decreased by 5.0% to RMB95.4 million (US$13.1 million), with an improved gross margin of 70.4%. Operating expenses decreased by 12.5% due to efficiency measures. Net loss narrowed to RMB108.0 million (US$14.9 million). The company's cash position stood at RMB533.0 million (US$73.3 million) as of June 30, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.76%
Tags
-
Rhea-AI Summary

Burning Rock Biotech has announced its intention to delist its American Depositary Shares (ADSs) from the London Stock Exchange (LSE) and cancel their listing on the Official List of the UK Financial Conduct Authority. The company cites sustained low trading volume and liquidity of its ADSs on the LSE as the primary reason for this decision, along with the costs associated with maintaining the listing. The delisting is expected to take effect on or around September 18, 2024. Importantly, Burning Rock's ADSs will continue to trade on the Nasdaq Global Market after the LSE delisting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
-
Rhea-AI Summary

Burning Rock Biotech has regained compliance with NASDAQ's minimum bid price requirement. The company received a notification from NASDAQ on May 30, 2024, confirming the compliance. Previously, on December 29, 2023, Burning Rock was notified of non-compliance due to its American depositary shares (ADSs) trading below $1.00 for 30 consecutive business days. To address this, the company adjusted the ratio of its ADSs from 1:1 to 1:10, effective May 15, 2024. This adjustment helped maintain a closing bid price of $1.00 or higher for 10 consecutive business days, leading to the regaining of compliance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
Rhea-AI Summary

Burning Rock Biotech (NASDAQ: BNR) has announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) in China. This partnership aims to enhance diagnostic methods and enable better treatment choices for cancer patients. The collaboration will focus on developing CDx products for Bayer's precision cancer therapies. Burning Rock's CEO, Mr. Han, emphasized the commitment to global development in cancer diagnosis and treatment, aiming to set high standards and provide more effective treatment options through this partnership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.3%
Tags
none
Burning Rock Biotech Ltd

Nasdaq:BNR

BNR Rankings

BNR Stock Data

28.72M
6.63M
0.04%
64.46%
0.47%
Diagnostics & Research
Healthcare
Link
China
Guangzhou